Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest
Fig 11
XPC mRNA and protein analysis.
Analysis of XPC in a) RT-PCR (n = 3) and b) Western Blot (n = 3) as fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as mean ± SEM with c) one representative western blot showing A549 untreated, A549 treated with 11 μM cisplatin, A549rCDDP2000 untreated, A549rCDDP2000 treated with 11 μM cisplatin and A549rCDDP2000 treated with 34 μM cisplatin.
doi: https://doi.org/10.1371/journal.pone.0181081.g011